全部

1·Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer?

PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用？ ？

2·Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.

苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。

3·The inhibitor of VEGF receptor tyrosine kinase was introduced in detail.

详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。

4·JAK2 is a constitutive protein tyrosine kinase (PTK) which can activate JAK-STAT signaling.

JAK2是一种组成性酪氨酸激酶，能激活JAK - STAT信号传导途径。

5·Objective: to review the progress in the research of tyrosine kinase inhibitors in recent years.

目的：对近年来酪氨酸激酶抑制剂的研究进展作以综述。

6·Binding of FLT3L to its cognate tyrosine kinase receptor, FLT3, activates STAT3 and STAT5 (1, 3).

FLT3L结合到与它同源的酪氨酸激酶的受体FLT3结合激活STAT3和STAT 5 (1,3)。

7·Secondary FLT3-TKD mutations are associated with treatment failure with tyrosine kinase inhibitors.

继发性FLT3 - TKD突变与酪氨酸激酶抑制剂治疗失败有关。

8·HNMPA-AM3 -the insulin receptor tyrosine kinase inhibitor could block the anti-apoptosis effect of insulin.

胰岛素受体自身酪氨酸磷酸化抑制剂一一HNMPA一AM3可以阻断胰岛素的抗凋亡作用。

9·ObjectiveTo study the abnormity and clinical value of tyrosine kinase signaling pathway in lung adenocarcinoma.

目的探讨肺腺癌患者酪氨酸激酶传导通路的异常和临床预后的关系。

10·Objective: to establish a method of detecting insulin receptor tyrosine kinase (IRTK) activity from erythrocytes.

目的：建立红细胞胰岛素受体酪氨酸蛋白激酶(IRTK)的活性测定法。